Find the latest pharmaceutical market place for APIs enquiry about Atomoxetin Hydrochloride on PharmaCompass.com.

Atomoxetine HCl API needed in Brazil [ENA19954]

An independent consultant based in Brazil having 30+ years of experience in the area of sourcing and foreign trade is looking for suppliers of Atomoxetine HCl API for commercial purposes. The suppliers must support this enquiry with USDMF, CEP & CoA.

Reply

12 Jul 2024

Atomoxetine HCl (50 kg - 60 kg) API needed in Canada [ENA17467]

A specialty biopharma company based in Belgium that focuses on innovation, reinvention and optimization of existing medications is looking for suppliers of Atomoxetine HCl (50 kg - 60 kg) API for commercial purposes. The suppliers must support this enquiry with USDMF, CEP & CoA.

Reply

05 Jul 2023

palestine-flag-png-27 Flag

Atomoxetine Hydrochloride & Famotidine APIs needed in Palestine [ENA07811]

A company specializing in the development, production and marketing of generic and branded pharmaceuticals is looking for suppliers of Atomoxetine Hydrochloride & Famotidine APIs. The required quantity is 2 kg for research purposes & 100 kg for commercial purposes for each. The suppliers must support this enquiry with GMP or CEP and DMF.

Reply

06 Jul 2020

india-flag Flag

BP Grade Atomoxetine (1 kg) API needed in India [ENA05459]

An Indian based trader and supplier of a wide range of active pharmaceutical ingredients and intermediates is looking for suppliers of BP Grade Atomoxetine (1 kg) API.

Reply

16 Oct 2019

Atomoxetine Hydrochloride API (50 kg) needed in Egypt [ENA02976]

An Egyptian trading company is looking for suppliers of Atomoxetine Hydrochloride API (50 kg) for their customer.

Reply

18 Dec 2018

Enquiry//Lacosamide, Rivaroxaban, Abiraterone Acetate & other APIs needed for Latin America [ENA00141]

An organization based in Mumbai, India, which was established over a decade ago to cater to the needs of pharmaceutical companies is searching for suppliers of 10-15kg of Abiraterone Acetate for Argentina and 1-2kg for R&D Development of Rivaroxaban, Vardenafil, Lacosamide and Atomoxetine for Mexico. The products need to be supported with a WHO/Local GMP certificate.

Reply

20 Dec 2016